Edition:
India

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

414.75INR
16 Aug 2019
Change (% chg)

Rs-2.30 (-0.55%)
Prev Close
Rs417.05
Open
Rs419.85
Day's High
Rs424.00
Day's Low
Rs410.10
Volume
312,082
Avg. Vol
437,911
52-wk High
Rs678.80
52-wk Low
Rs350.40

About

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New... (more)

Overall

Beta: 0.05
Market Cap(Mil.): Rs1,272,113.00
Shares Outstanding(Mil.): 2,399.31
Dividend: 3.50
Yield (%): 0.66

Financials

  SUN.BO Industry Sector
P/E (TTM): 28.37 29.89 32.67
EPS (TTM): 18.69 -- --
ROI: -- 14.89 14.48
ROE: -- 16.01 15.78

BUZZ-India's Sun Pharma at near 4-week low; chart points to more downside

** Shares of Sun Pharmaceutical Industries Ltd fall about 4% to 386 rupees, their lowest since May 16

11 Jun 2019

MEDIA- Sun Pharmaceutical plans to start developing its own medicines - Bloomberg

-- Note: Reuters has not verified this story and does not vouch for its accuracy

22 May 2019

BUZZ-India's Sun Pharma may test a support at 367 rupees - Technicals

** Shares of Sun Pharmaceutical Industries Ltd, down as much as 7.2%, may test a support at 366.88 rupees

16 May 2019

Indian shares snap losing spree, inflation data lifts sentiment

May 14 Indian shares snapped a nine-session losing spree to end higher on Tuesday, with pharmaceutical stocks among the top boost, a day after the country's retail inflation data brought hopes of a key interest rate cut in June.

14 May 2019

MEDIA-India's Sun Pharmaceuticals to set up an ethics committee to oversee corporate governance-related matters - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy

06 May 2019

BUZZ-India's Sun Pharma falls after U.S. FDA observations on co's Dadra plant

** U.S. FDA on Friday issued Form 483 with 11 observations after inspection of co's Dadra facility during March 22-29

30 Apr 2019

MEDIA-SEBI asks India's Sun Pharma to explain alleged fund diversion of 420 bln rupees - Business Standard

- Note: Reuters has not verified this story and does not vouch for its accuracy

06 Mar 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates